Inhibitor Therapeutics (INTI) 10-K15 Apr 142013 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2013	Apr. 11, 2014	Jun. 28, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'HedgePath Pharmaceuticals, Inc.	'	'
Entity Central Index Key	'0001042418	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	18,888,971	'
Entity Public Float	'	'	$152,743

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$217	$857,702
Other current assets	'	78,733
Prepaid assets	10,000	'
Total current assets	10,217	936,435
Total assets	10,217	936,435
Current liabilities:	'	'
Accounts payable	287,072	368,613
Notes payable, related party	68,428	'
Accrued payroll liabilities	'	191,340
Other liabilities	52,500	'
Accrued interest	1,923	'
Due to related party	366,130	'
Total current liabilities	776,053	559,953
Liabilities subject to compromise:	'	'
Priority claims	'	23,450
Accounts payable and other unsecured creditors	'	422,316
Other liabilities	'	63,500
Total liabilities subject to compromise	'	509,266
Total liabilities	776,053	1,069,219
Commitments and contingencies (note 4)	'	'
Stockholders' deficit:	'	'
Preferred stock value	'	'
Common Stock, $0.0001 par value in 2013 and no par value in 2012; 340,000,000 and 100,000,000 shares authorized in 2013 and 2012, respectively; 18,888,971 and 15,560,504 shares issued and outstanding in 2013 and 2012, respectively	1,889	'
Additional paid-in capital	27,479,913	26,279,815
Accumulated deficit	-28,247,655	-26,412,599
Total stockholders' deficit	-765,836	-132,784
Total liabilities and stockholders' deficit	10,217	936,435
Series A Preferred Stock [Member]	'	'
Stockholders' deficit:	'	'
Preferred stock value	$17	'

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Preferred stock, par value	$0.00	'
Preferred stock, no par value	'	'
Preferred stock, shares authorized	9,500,000	1,000,000
Common stock, par value	$0.00	'
Common stock, no par value	'	'
Common stock, shares authorized	340,000,000	100,000,000
Common stock, shares issued	18,888,971	15,560,504
Common stock, shares outstanding	18,888,971	15,560,504
Series A Preferred Stock [Member]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	500,000	'
Preferred stock, shares issued	170,001	'
Preferred stock, shares outstanding	170,001	'

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
Statements of Operations (USD $)	Dec. 31, 2013	Dec. 31, 2012
Revenues:	'	'
Total revenues	'	'
Expenses:	'	'
Chapter 11 expenses	117,324	'
Research and development	1,065,169	'
General and administrative	817,316	560,670
Total expenses	1,999,809	560,670
Loss from operations	-1,999,809	-560,670
Interest expense	-1,923	'
Gain on reorganization:	'	'
Realized gains	'	80,369
Gain on extinguishment of debt	'	666,667
Gain on settlement of pre-petition claims	166,676	'
Gain on reorganization	166,676	747,036
Net (loss) income	($1,835,056)	$186,366
Basic and diluted (loss) earnings per share	($0.10)	$0.01
Weighted average common stock shares outstanding	17,940,586	13,646,638

Statements_of_Stockholders_Def

Statements of Stockholders' Deficit (USD $)	Total	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2011	($369,150)	'	$12,660,504	$26,229,815	($26,598,965)
Beginning balance, shares at Dec. 31, 2011	'	'	12,660,504	'	'
Issuance of stock	50,000	'	2,900,000	50,000	'
Net (loss) income	186,366	'	'	'	186,366
Ending balance at Dec. 31, 2012	-132,784	'	15,560,504	26,279,815	-26,412,599
Ending balance, shares at Dec. 31, 2012	15,560,504	'	15,560,504	'	'
Issuance of stock	1,050,004	17	'	1,049,987	'
Issuance of stock, shares	'	170,001	'	'	'
Issuance of restricted stock in lieu of cash payment under the Bankruptcy Plan	152,000	'	3,328,467	152,000	'
Issuance of restricted stock in lieu of cash payment under the Bankruptcy Plan, shares	'	'	'	'	'
Initiation of par value pursuant to agreement and plan of merger and reorganization	'	'	1,889	-1,889	'
Net (loss) income	-1,835,056	'	'	'	-1,835,056
Ending balance at Dec. 31, 2013	($765,836)	$17	$1,889	$27,479,913	($28,247,655)
Ending balance, shares at Dec. 31, 2013	18,888,971	170,001	18,888,971	'	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
Statements of Cash Flows (USD $)	Dec. 31, 2013	Dec. 31, 2012
Operating activities:	'	'
Net (loss) income	($1,835,056)	$186,366
Adjustments to reconcile net (loss) income to net cash flows from operating activities:	'	'
In-process research and development purchased with the issuance of preferred stock	1,020,004	'
Unrealized loss on investments	'	527
Gain on extinguishment of debt	'	-666,667
Expenses paid with the issuance of stock	'	50,000
Changes in assets and liabilities:	'	'
Other current assets	68,733	'
Accounts payable and other current liabilities	46,645	-34,492
Net cash flows from operating activities before reorganization items	-699,674	-464,266
Reorganization items:	'	'
Gain on reorganization	-166,676	'
Decrease in liabilities subject to compromise	-357,265	'
Net cash flows from operating activities	-1,223,615	-464,266
Financing activities:	'	'
Proceeds from related party advances	366,130	'
Net cash flows from financing activities	366,130	'
Net change in cash and cash equivalents	-857,485	-464,266
Cash and cash equivalents at beginning of period	857,702	1,321,968
Cash and cash equivalents at end of period	217	857,702
Supplemental disclosure of non-cash financing activity:	'	'
Reclassification of deposit to additional paid-in capital	30,000	'
Promissory notes issued in payment of related party obligations	68,428	'
Stock payments to officers and directors (liabilities subject to compromise) in lieu of cash payments under the Bankruptcy Plan	152,000	'
Expenses satisfied with the issuance of stock	'	50,000
Gain on extinguishment of debt	'	($666,667)

Corporate_overview

Corporate overview:	12 Months Ended
Corporate overview:	Dec. 31, 2013
Accounting Policies [Abstract]	'
Corporate overview:	'
	1	Corporate overview:
	Overview
	The accompanying audited financial statements of HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”, “HPPI”, “we”, “us” or similar terminology) as successor to Commonwealth Biotechnologies, Inc., a Virginia corporation (“CBI”), have been prepared by the Company as a going concern.
	As used herein, the term “Common Stock” means the Company’s common stock, $0.0001 par value per share.
	Nature of the Business
	CBI was a specialized life sciences outsourcing business that offered certain peptide-based discovery chemistry and biology products and services through Mimotopes Pty Limited (“Mimotopes”), a wholly-owned subsidiary of CBI. On January 20, 2011, CBI filed a voluntary petition captioned In re Commonwealth Biotechnologies, Inc., Case No. 11-30381-KRH (the “Chapter 11 case”) in the United States Bankruptcy Court for the Eastern District of Virginia (the “Bankruptcy Court”) seeking relief under the provisions of Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”). On April 7, 2011, the Bankruptcy Court approved the private sale of the Mimotopes business unit for a net sales price of $850,000. The sale closed on April 29, 2011.
	On August 12, 2013, in furtherance of CBI’s emergence from bankruptcy as described further below, CBI effected a “short-form” reincorporation merger with HPPI, a newly created and wholly owned Delaware subsidiary of CBI, pursuant to which CBI merged with and into HPPI, with HPPI surviving the merger and with the effect of CBI becoming reincorporated as a Delaware corporation and changing its corporate name. Each outstanding share of CBI was converted into one share of HPPI. HPPI’s Certificate of Incorporation (and thus the Certificate of Incorporation of the surviving company) authorizes the issuance of up to 340,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. The par value was changed from no par value to $0.0001, which par value is customary for newly formed Delaware corporations.
	As described further below, the Company’s present business is the development of the currently-marketed drug itraconazole (currently approved by the U.S. Food and Drug Administration (“FDA”) as an anti-fungal agent) for the treatment of certain cancers.
	Pre-Bankruptcy and Emergence from Bankruptcy
	On January 4, 2013, CBI filed an Amended Plan of Reorganization (the “Plan”) with the Bankruptcy Court. The Plan was approved by a vote of creditors and CBI stockholders on March 21, 2013. CBI received an auction fee of $30,000 from Hedgepath, LLC, a Florida limited liability company, (which fee was a binding, irrevocable offer for the purchase of a portion of CBI’s equity interests) in addition to the contribution of Assets as described below. Hedgepath, LLC was the winning bidder for CBI, which is more fully described below in Post-Bankruptcy Business of HPPI-General. This auction fee was recognized as an increase in additional paid-in capital when the Contribution Agreement (as defined below) became effective.
	On March 29, 2013, the Bankruptcy Court entered an order (the “Confirmation Order”) confirming the Plan pursuant to Chapter 11 of the Bankruptcy Code. Under the terms of the Plan, and pursuant to the Contribution Agreement (as described further below), Hedgepath, LLC contributed and assigned the Assets (as such term is defined below) to HPPI, as the reorganized debtor, in exchange for the right to receive 90% of fully diluted voting equity in HPPI (in the form of the Series A Preferred Stock) on the date of issuance, with the prior stockholders of CBI retaining approximately 10% voting equity in HPPI, represented by 100% of the issued and outstanding shares of Common Stock.
	Contribution Agreement
	On August 13, 2013, the Company entered into a Contribution Agreement, dated as of August 13, 2013 (the “Contribution Agreement”), by and between the Company and Hedgepath, LLC pursuant to which, and subject to the terms and conditions contained therein, in exchange for the right to receive 170,001 shares of the Company’s newly created Series A Convertible Preferred Stock (the “Series A Preferred Stock”), representing 90% of the fully diluted voting securities of the Company as of the date of issuance (or 170,000,739 shares of Common Stock on an as converted basis), Hedgepath, LLC contributed and/or assigned various assets and contract rights to the Company associated with the going forward business of the Company (collectively, the “Assets”) to the Company as described below.

		(i)	U.S. Provisional Patent Application 61-813,122, “Prostate-Specific Antigen as Biomarker for Hedgehog Pathway Inhibitor Treatment and Prognostic Monitoring of Prostate Cancer” (previously assigned to Hedgepath, LLC by Dr. Frank E. O’Donnell, Jr. and Nicholas J. Virca, as inventors);

		(ii)	U.S. Provisional Patent Application 61-813,823, “Treatment and Prognostic Monitoring of Cancer Using Hedgehog Pathway Inhibitors” (previously assigned to Hedgepath, LLC by Dr. Frank E. O’Donnell, Jr. and Nicholas J. Virca, as inventors);

		(iii)	Assignment of Patents, dated November 1, 2012, by Dr. Frank E. O’Donnell, Jr. in favor of Hedgepath, LLC;

		(iv)	Assignment of Patents, dated November 1, 2012, by Nicholas J. Virca in favor of Hedgepath, LLC;

		(v)	Consulting Agreement, dated and effective as of September 1, 2012, by and between HPPI (as successor to Hedgepath, LLC) and Emmanuel Antonarakis, MD (“Antonarakis”).

		(vi)	Confidentiality and Intellectual Property Assignment Agreement, dated and effective September 1, 2012, between Antonarakis and HPPI (as successor to Hedgepath, LLC), which includes all intellectual property, know-how and other assets assigned to Hedgepath, LLC by Antonarakis under such agreement.

		(vii)	Consulting Agreement, effective as of April 11, 2013, by and between Hedgepath, LLC and Arianne Consulting, Inc. (“Arianne”); and

		(viii)	Confidentiality and Intellectual Property Assignment Agreement, dated and effective April 11, 2013, between Arianne and Hedgepath, LLC , which includes all intellectual property, know-how and other assets assigned to Hedgepath, LLC by Arianne under such agreement.
	The Contribution Agreement was entered into to carry out the purposes and intent of the Plan filed by CBI and confirmed by the Bankruptcy Court in connection with the Chapter 11 case.
	Hedgepath, LLC is a development stage pharmaceutical company. Since its formation in late 2011, Hedgepath, LLC has sought, among other pharmaceutical business opportunities, to acquire technology rights and to conduct activities related to the development of the currently-marketed drug itraconazole (currently FDA approved as an anti-fungal agent) for the treatment of certain cancers (the “Itra Business Opportunity”). Hedgepath, LLC has expended approximately $0.1 million acquiring assets and developing the ITRA Business Opportunity including approximately $82,500 on technical and medical consulting and $15,000 on option fees related to intellectual property agreement that has since expired.
	In accordance with the Plan, and as a result of the transactions contemplated by the Contribution Agreement, from and after August 13, 2013, HPPI will be engaged in the Itra Business Opportunity. The Assets contributed to the Company by Hedgepath, LLC represent the assets and rights heretofore developed or acquired by Hedgepath, LLC related to the Itra Business Opportunity, and by virtue of the Contribution Agreement, the Company acquired all of Hedgepath, LLC’s right, title and interest in and to the Assets.
	As part of the Contribution Agreement, Hedgepath, LLC, which owned a certain claim against CBI in the amount of $52,500, payable to a third party service provider, contributed such claim to the Company. HPPI has agreed to issue to such service provider a number of restricted shares of its Common Stock to be determined based on the valuation of the shares to be issued to purchasers in connection with HPPI’s planned $5 million offering of securities as described in the Plan. Such shares of Common Stock are to be issued to such service provider within five (5) business days of the final determination of such valuation (as memorialized in the final transaction documentation for such offering).
	Hedgepath, LLC did not contribute any of its liabilities to the Company in connection with the Contribution Agreement, and retained all of its assets other than those related to the Itra Business Opportunity.
	In conjunction with the execution of the Contribution Agreement, the Company has expensed, as in-process research and development cost, approximately $1.0 million. The value was calculated by taking 90% of the market capitalization on the date the assets were contributed to reflect the 90% ownership exchanged for the assets contributed by Hedgepath, LLC.
	Post-Bankruptcy Business of HPPI—General
	As a result of the aforementioned transactions, as of August 13, 2013 the Company is a clinical stage biopharmaceutical company that endeavors to discover, develop and commercialize innovative therapeutics for patients with certain cancers. The Company is currently focused on the development of therapies for certain cancers, with initial emphasis on skin, prostate and lung cancers in the U.S. market, based upon the use of the currently marketed anti-fungal drug itraconazole. The Company believes that itraconazole could affect the Hedgehog signaling pathway in cells, a major regulator of many fundamental cellular processes, which could, in turn, impact the development and growth of certain cancers.
	Itraconazole is FDA approved for and extensively used to treat fungal infections and has an extensive history of safe and effective use in humans. The Company has developed, optioned and is seeking to acquire and/or license, intellectual property and know-how related to the treatment of cancer patients using itraconazole and has applied for patents to cover the Company’s inventions.
	Net (loss) income per common share
	The following is a reconciliation of the numerators and denominators of the basic and diluted earnings per common share computations for the years ended December 31, 2013 and 2012.


			2013			2012
	Basic:
	Net (loss) income attributable to common stockholders		$	(1,835,056	)	$	186,366
	Weighted average common shares outstanding			17,940,586			13,646,638

	Basic (loss) earnings per common share		$	(0.10	)	$	0.01


	Diluted:
	Effect of dilutive securities:
	Net (loss) income attributable to common stockholders		$	(1,835,056	)	$	186,366
	Adjustments to income for dilutive options and warrants			—			—

				(1,835,056	)		186,366
	Weighted average common shares outstanding			17,940,586			13,646,638
	Effect of dilutive options and warrants			—			—

	Diluted weighted average common shares outstanding			17,940,586			13,646,638

	Diluted (loss) earnings per common share		$	(0.10	)	$	0.01

Basic earnings per common share is calculated using the weighted average shares of Common Stock outstanding during the period. Common equivalent shares from stock options and warrants using the treasury stock method, are also included in the diluted per share calculations unless the effect of inclusion would be antidilutive. During the year ended December 31, 2012, outstanding stock options and warrants of 1,220,443 were not included in the computation of diluted earnings per common share, because to do so would have had an antidilutive effect because the outstanding exercise prices were greater than the average market price of the common shares during the relevant periods.

Liquidity_and_managements_plan

Liquidity and management's plans:	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Liquidity and management's plans:	'
	2	Liquidity and management’s plans:
	A continued lack of adequate cash resulting from the Company’s bankruptcy, the sale of CBI’s principal assets, and the resulting inability to generate cash flow from operations or to raise capital from external sources forced the Company to substantially curtail or cease operations and, therefore, had a material adverse effect on its business. Consequently, during 2012 and 2013, the Company’s business has undergone substantial reductions in relation to size, scale and scope of activities.
	As a result of the foregoing circumstances, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s previous and current independent auditors have included a paragraph emphasizing “going concern” uncertainty in their report on the 2012 and 2013 financial statements. The financial statements included herein do not include any adjustments relating to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.
	The Company currently has cash and cash equivalents of $217 as of December 31, 2013, and has and will therefore rely on loans from insiders and affiliates to fund its operations until the Company is able to raise additional capital. Subsequent to December 31, 2013, working capital advances as of the date of this Report from Hedgepath, LLC amounted to approximately $100,000, and have been used for officer and employee salaries, legal and professional fees.

	The Company intends to finance its research and development, commercialization and distribution efforts and its working capital needs primarily through:

		•	partnering with other pharmaceutical companies to assist in the supply, manufacturing and distribution of our products for which we would expect to receive upfront milestone and royalty payments;

		•	licensing and joint venture arrangements with third parties, including other pharmaceutical companies where the Company would receive funding based on out-licensing its product to augment their product profile in the treatment of cancers;

		•	receiving government or private foundation grants which would be awarded to the Company to further develop our current and future anti-cancer therapies; and

		•	securing proceeds from public and private financings and other strategic transactions.
	However, there can be no assurance that any of these plans will be implemented on commercially reasonable terms, if at all.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	3	Summary of Significant Accounting Policies:
	Recent accounting pronouncements
	In July 2013, the FASB issued ASU 2013-11– Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). This guidance requires the unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset. When a deferred tax asset is not available, or the asset is not intended to be used for this purpose, an entity should present the unrecognized tax benefit in the financial statements as a liability. The guidance will become effective for us at the beginning of our first quarter of fiscal 2014. The Company does not expect the adoption of this guidance will have a material impact on its financial statements.
	In January 2013, the FASB issued ASU 2013-01 – Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities (“ASU 2013-01”). The amended guidance limits the scope of balance sheet offsetting disclosures to derivatives, repurchase agreements, and securities lending transactions to the extent that they are offset in the financial statements or subject to an enforceable master netting arrangement or similar agreement. The guidance became effective for us at the beginning of our fourth quarter of fiscal 2013. The adoption of this guidance had no impact on the Company’s financial statements.
	Estimates
	The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
	Revenue Recognition
	The Company currently has no ongoing source of revenues. Any miscellaneous income is recognized when earned by the Company.
	Cash and Cash Equivalents
	The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts.
	Research and Development Expenses
	Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company.

	Accounting for Enterprises in Reorganization
	Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 852—Reorganizations (“ASC Topic 852”), which is applicable to companies in Chapter 11, generally does not change the manner in which financial statements are prepared. However, it does require that the financial statements for periods subsequent to the filing of the Chapter 11 petition distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of the business. Revenues, expenses, realized gains and losses, and provisions for losses that can be directly associated with the reorganization and restructuring of the business must be reported separately as reorganization items in the statements of operations beginning in the quarter ending March 31, 2011. The balance sheet must distinguish prepetition liabilities subject to compromise from both those prepetition liabilities that are not subject to compromise and from post-petition liabilities. Liabilities that may be affected by a plan of reorganization must be reported at the amounts expected to be allowed by the Bankruptcy Court, even if they may be settled for lesser amounts. In addition, cash flows from reorganization items must be disclosed separately in the statement of cash flows. The Company became subject to ASC Topic 852 effective on January 20, 2011, and has segregated those items as outlined above for all reporting periods after such date. The Company officially emerged from bankruptcy on April 17, 2013, followed by the reincorporation merger, which satisfied the final condition to effectiveness of the Plan as detailed in Note 1.
	Income taxes
	Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the consolidated financial statements for the years ended December 31, 2013 or 2012.

Supply_and_License_Agreement

Supply and License Agreement	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Supply and License Agreement	'
	4	Supply and License Agreement
	On September 3, 2013, the Company entered into an exclusive Supply and License Agreement (the “Supply and License Agreement”) with Mayne Pharma International Pty Ltd., a company incorporated in Australia (“Mayne Pharma”), pursuant to which Mayne Pharma agreed to: (i) supply the Company with its patented formulation of the drug itraconazole, known as SUBATM-Itraconazole, in a particular dose formulation (the “Product”) for the treatment of human patients with cancer via oral administration (the “Field”) (with the initial areas of investigation being prostate, lung and skin cancer) in the United States (the “Territory”), (ii) provide the Company with an exclusive license to use and develop the intellectual property related to the Product in the Field and in the Territory and (iii) participate in a joint development committee with the Company (“JDC”) to clinically develop the Product in the Field and in the Territory. The Company will pursue the development of the Product for treatment of a variety of cancers with a focus on clinical development, seeking regulatory approvals and, if regulatory approval is obtained, marketing in the United States.
	Pursuant to the Supply and License Agreement, the Company, with the assistance of Mayne Pharma through the JDC and subject to certain approval rights of Mayne Pharma, will develop and exploit the Product through a development plan which will be authorized by the JDC and updated as necessary. The license granted to the Company under the Supply and License Agreement may only be assigned or sub-licensed with the prior approval of Mayne Pharma. In addition, in support of the exclusive nature of the Supply and License Agreement, during the term, Mayne Pharma is prohibited from directly or indirectly importing, promoting, marketing, distributing or selling the Product in the Territory and in the Field. If any other form of the Product manufactured by Mayne Pharma is sold as a result of any off label use, the Company shall be entitled to a royalty on such off-label sales. Further, the Company may not develop products that are competitive with the Product, which period extends for a certain period following the end of the term.
	Under the Supply and License Agreement, the Company is responsible for obtaining all of its requirements for the Product from Mayne Pharma, including for use in clinical trials, importation, promotion, marketing, sale and distribution in the Territory. The Company and Mayne Pharma have established certain minimum floor prices that the Company must pay per unit of the Product and minimum order quantities for the Product.
	Any intellectual property created by the Company, either on its own or jointly with Mayne Pharma, relating to the Product in the Field will be owned by the Company, except that the Company has granted Mayne Pharma an exclusive, perpetual, irrevocable, royalty free license to copy and exploit such developed intellectual property outside of the Territory.

	Although the Supply and License Agreement is effective immediately, it remained subject to early termination by Mayne Pharma if certain conditions (the “Conditions”) were not met by December 16, 2013. Such Conditions include: (i) the Company shall have raised $5 million in an equity financing (or such lesser amount as may be agreed to by Mayne Pharma) (the “Equity Financing”); (ii) a representative of Mayne Pharma shall have been appointed to the Company’s board of directors, and Mayne Pharma and the Company shall have entered into an agreement granting Mayne Pharma certain board appointment rights; (iii) Mayne Pharma shall, pursuant to customary definitive documentation to be negotiated by the parties, acquire from the Company, as part of the consideration under the Supply and License Agreement, 170,001 shares of the Company’s Series A Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), representing, on an as fully converted, fully diluted basis, 45% of the issued and outstanding shares of capital stock of the Company (prior to the Equity Financing (as defined below) and the anticipated adoption by the Company of an equity incentive plan); (iv) Hedgepath, LLC (an affiliate of the Company who currently has the right to receive shares of Series A Preferred Stock), Nicholas J. Virca (the Company’s President and Chief Executive Officer) (“Virca”) and Mayne Pharma shall have entered into an agreement providing for certain restrictions on transfers and ownership of Company equity; (v) the Company and Mayne Pharma shall have entered into an agreement granting Mayne Pharma and accredited investors introduced to the Company by Mayne Pharma certain participation rights in future Company equity financings; (vi) the Company shall have (a) received a written estimate from a credible contract research organization reasonably acceptable to Mayne Pharma relating to the Company’s proposed clinical trials and (b) provided reasonable assurances to Mayne Pharma that the Product will be available for commercial launch by a specified date; and (vii) Virca and Frank E. O’Donnell, Jr., the Company’s Executive Chairman, shall have entered into customary agreements regarding their positions with the Company. Due to the contingent nature of the Supply and License Agreement, none of Series A Preferred Stock has been issued to Mayne Pharma as of the date of this Report and, therefore, there is no accounting treatment applicable.
	Subject to earlier termination if the Conditions are not met as described above, the term of the Supply and License Agreement shall last until the later of: (i) 10 years from the target launch date of the Product for the treatment of human patients with cancer via oral administration or (ii) the date on which all issued patents of Mayne Pharma or any of its affiliates referred to in the Supply and License Agreement have lapsed or expired.
	The Supply and License Agreement is further subject to termination in certain circumstances, including: (i) by either party in the event of (a) a material default that is not cured within a specified number of days after notice is received or is not capable of remedy, (b) if marketing authorizations for the Product are not obtained prior to the agreed upon target launch date for the Product or (c) a force majure event precluding performance by the other party for a specified period of time, (ii) the voluntary or involuntary bankruptcy of either party, (iii) by Mayne Pharma if either Hedgepath, LLC or Virca breach their respective agreements with Mayne Pharma to restrict the sale and or transfer of their shares of Company equity and such breach is not cured within a specified number of days after notice is received or such breach is not capable of remedy, (iv) by Mayne Pharma if the Company breaches certain of its obligations relating to the Conditions (once they are satisfied) and such breach is not cured within a specified number of days after notice is received or such breach is not capable of remedy, (v) by Mayne Pharma if, under certain circumstances, the Company fails to purchase the minimum agreed upon amounts of Product in any given year or (vi) by Mayne Pharma, under certain circumstances, upon a change of control of the Company.
	On December 17, 2013, the Company entered into Amendment No. 1 to the Supply and License Agreement (the “Amended Supply and License Agreement”) with Mayne Pharma. The Amended Supply and License Agreement amends the Agreement as follows:
	(i) the date by which the Conditions (as defined below) must be met was extended from December 16, 2013 to February 28, 2014;
	(ii) Mayne Pharma had agreed to reimburse all reasonable third party expenses incurred in the conduct of the activities set out in, and in accordance with, the development plan as set forth in the Agreement (the “Development Plan”), or otherwise related to the Product by the Company from the date of the Amended Supply Agreement through February 28, 2014; provided however that (i) such expenses may not exceed $100,000, (ii) the Company must receive prior written approval from Mayne Pharma prior to incurring such expenses, and (iii) any third party engaged to provide clinical or other services to the Company must first enter into an agreement with the Company to assign all intellectual property rights developed by or on behalf of it in providing such services to the Company. Furthermore, such reimbursement must be repaid by the Company to Mayne Pharma once the Conditions have been met or waived by Mayne Pharma; and
	(iii) if Mayne Pharma terminated the Agreement, then the Company will assign to Mayne Pharma all intellectual property rights created or developed in the conduct of the activities set out in, and in accordance with, the Development Plan or otherwise related to the Product that have been created or developed between the date of the Amended Supply and License Agreement and February 28, 2014. Such assignment will occur whether such rights were created or developed by or on behalf of the Company, its affiliates or any third party providing services to the Company or its affiliates; provided however, that: (i) all rights of the Company in the HP Patents (as defined in the Agreement) and all intellectual property rights of the Company created or developed (either by the Company or jointly with Mayne Pharma) prior to the date of the Amended Supply and License Agreement shall remain the exclusive property of the Company as provided for in the Agreement and (ii) if the Conditions have been waived by Mayne Pharma or satisfied as of or prior to the February 28, 2014, all provisions of the Agreement relating to the ownership of intellectual property rights relating to the Product shall be governed by the original provisions of the Agreement and this provision will be terminated upon the waiver by Mayne Pharma, or satisfaction, of the Conditions.
	As provided for in the Agreement, as amended, Mayne Pharma could have terminated the Agreement since certain conditions were not met by February 28, 2014.
	On March 5, 2014, the Company entered into Amendment No. 2 to the Supply and License Agreement (the “Amended Supply and License Agreement”) with Mayne Pharma. The Amended Supply and License Agreement amends the Agreement as follows:
	(i) the date by which the Conditions (as defined below) must be met was extended from February 28, 2014 to March 31, 2014;
	(ii) the Company has agreed to use reasonable efforts to progress the conduct of the activities set out in, and in accordance with, the development plan as set forth in the Agreement (the “Development Plan”), and to seek reimbursement of relevant amounts in accordance with the Agreement;
	(iii) the Company and Mayne Pharma acknowledged and agreed that warrants may be issued in connection with an Equity Financing (as defined below) and further agreed that in the event that warrants are issued in connection with an Equity Financing, Mayne Pharma will receive a warrant on the same terms as the warrants issued in the Equity Financing for such a number of shares that will ensure that Mayne Pharma will hold at least 30% of the issued and outstanding shares of capital stock of the Company on a fully diluted, fully converted basis following the Equity Financing;
	(iv) if the Company does not (i) submit a complete Investigational New Drug (“IND”) application to the United States Food and Drug Administration (the “FDA”) for the Product for at least one indication in the Field and commence dosing patients in at least two phase II or phase II/III clinical trials across at least two indications in the Field by March 31, 2015 or (ii) submit an application for a new drug application to the FDA for at least one indication by March 31, 2016, then Mayne Pharma may, by notice to Frank E. O’Donnell, Jr. M.D., the Company’s Executive Chairman, and Nicholas J. Virca, the Company’s President and Chief Executive Officer, require each of them to resign from the Company, in which case each of Hedgepath LLC, Mr. Virca and Dr. O’Donnell will forfeit all of their respective unvested Company options, and Mayne Pharma will have the right to purchase all issued and outstanding shares of the Company’s capital stock held by Mr. Virca and Dr. O’Donnell at market price, and neither Mr. Virca nor Dr. O’Donnell will be entitled to receive any severance or similar payments from the Company;
	(v) in the event that Dr. O’Donnell or Mr. Virca are removed or resign from the Company’s board of directors, any replacement appointees will need to obtain unanimous approval from the remaining board members; and
	(vi) Mayne Pharma waived its right to require the Company to obtain a written estimate from a contact research organization relating to the timing and completion of phase II trials on the use of the Product in the Field and waived its right to reasonably expect that the Product would launch by a date agreed upon the Company and Mayne.
	Mayne Pharma could have terminated the Agreement, as amended, if certain conditions were not met by March 31, 2014. That date was extended to April 25, 2014 by mutual agreements. The Company is continuing efforts to meet those conditions. No transactions under the original or amended Supply and License Agreement have transpired to date.

Gain_on_Reorganization

Gain on Reorganization	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Gain on Reorganization	'
	5	Gain on Reorganization:
	The Company has recognized gains of $166,676 and $747,036, which are included in gain on reorganization in the accompanying statements of operations for the years ended December 31, 2013 and 2012, respectively, as a result of final payments under the Chapter 11 reorganization plan.

Debt

Debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt	'
	6	Debt:
	On September 4, 2008, CBI completed the issuance of a $500,000 convertible promissory note (“the Note”) payable to Fornova Pharmaworld, Inc. (“the Holder”). On February 10, 2012, the CBI filed a claim against Fornova in Bankruptcy Court. CBI was disputing Fornova’s claim that it was owed $500,000 plus accrued interest relating to a convertible note that was originated in 2007. CBI was seeking to have the claim disallowed in its entirety or, in the alternative, reclassified as an equity investment. In October 2012, CBI’s claim against Fornova was approved by the Bankruptcy Court. Fornova’s claim was disallowed in its entirety. Effective September 30, 2012, principal and accrued interest in the amount of $666,667 was written off and a gain on extinguishment of debt was recognized.

Property_and_Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2013
Text Block [Abstract]	'
Property and Equipment	'
	7	Property and Equipment:
	Property and Equipment relating to CBI consisted of the following:


			December 31,
			2013		2012
	Furniture, fixtures, office and computer equipment		$	—	$	53,575
	Other			—		9,077

			$	—	$	62,652

	Less accumulated depreciation			—		(62,652	)

			$	—	$	—

	There was no depreciation expense for the years ended December 31, 2013 and 2012.

Other_Assets

Other Assets	12 Months Ended
	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Other Assets	'
	8	Other Assets:
	As of December 31, 2012, other current assets include $75,000 relating to cash held in escrow by the Company’s bankruptcy attorneys. These funds were used to pay legal fees as approved by the Bankruptcy Court.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	9	Income Taxes:
	The difference between expected income tax benefits and income tax benefits recorded in the financial statements is explained below:


			December 31,
			2013			2012
	Income taxes (benefit) computed at statutory rate		$	(627,319	)	$	—
	State income tax benefit, net			(63,688	)		(347	)
	Change in valuation allowance			691,007			347

			$	—		$	—

	The significant components of deferred income tax assets and liabilities consist of the following:


			December 31,
	Deferred tax assets (liabilities)		2013			2012
	In-process research and development		$	346,801		$	—
	Net operating loss carry forward			407,398			15,994,583
	R&D credit			2,584			52,600

				756,783			16,047,183

	Less: valuation allowance			(756,783	)		(16,047,183	)

			$	—		$	—


	In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized. The valuation allowance should be sufficient to reduce the deferred tax asset to the amount which is more likely than not to be realized. As a result, the Company recorded a valuation allowance with respect to all of the Company’s deferred tax assets.
	The Company has a federal net operating loss (“NOLs”) of approximately $1.1 million as of December 31, 2013. Under Section 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a “loss corporation”, as defined, there are annual limitations on the amount of the NOLs and other deductions which are available to the Company. The portion of the NOLs incurred prior to August 12, 2013 is subject to this limitation. As such, the use of these NOLs to offset taxable income is limited to approximately $35,000 per year and the Company has written off the deferred tax assets associated with the NOLs limited due to the ownership change that occurred on August 12, 2013. The Company’s State NOLS are approximately $1.1 million as of December 31, 2013. These loss carryforwards expire principally beginning in 2018 for federal and state purposes.

Chapter_11_Information

Chapter 11 Information	12 Months Ended
	Dec. 31, 2013
Reorganizations [Abstract]	'
Chapter 11 Information	'
	10	Chapter 11 Information:
	During the year ended December 31, 2013, the Company settled all pre-petition claims associated with the bankruptcy in cash and Common Stock. The Company paid $357,265 in cash and $152,000 in Common Stock to settle the claims. The Common Stock was valued using the 30 day average of the Company’s stock price. The $166,676 difference between pre-petition liabilities and the settled amount was recognized as gain on reorganization in the condensed statement of operations for the year ended December 31, 2013. During the year ended December 31, 2012, the Company sought to have a claim relating to a 2008 convertible promissory note disallowed. In October 2012, the claim was disallowed by the Bankruptcy Court. Consequently, principal and interest of approximately $500,000 and $166,667, respectively, were written off effective September 30, 2012. This write-off resulted in a gain on extinguishment of debt of $666,667. Other realized gains for 2012 were approximately $80,000 and resulted from changes in management’s estimates regarding the expected settlement amounts of liabilities subject to compromise.

Stockholders_Deficit

Stockholders' Deficit

12 Months Ended

Dec. 31, 2013

Equity [Abstract]

Stockholders' Deficit

Stockholders’ Deficit:

Employee Stock Plans

A 2002 Stock Incentive Plan was adopted by the Board of Directors and approved by the shareholders of CBI. However, all options were canceled on July 16, 2013, which was 90 days subsequent to the effective date of the emergence from bankruptcy.

A 2007 Stock Incentive Plan was adopted by the Board of Directors and approved by the shareholders of CBI. However, all options were canceled on July 16, 2013, which was 90 days subsequent to the effective date of the emergence from bankruptcy.

A 2009 Stock Incentive Plan was adopted by the Board of Directors and approved by the shareholders of CBI. There are no options outstanding under this plan.

Going forward, incentive awards may be in the form of stock options, restricted stock, restricted stock units and performance and other awards. In the case of incentive stock options, the exercise price will not be less than 100% of the fair market value of shares covered at the time of the grant, or 110% for incentive stock options granted to persons who own more than 10% of the Company’s voting stock. Options granted will generally vest over a three-year period from the date of grant and will be exercisable for ten years, except that the term may not exceed five years for incentive stock options granted to persons who own more than 10% of the Company’s outstanding common stock.

Stock-based compensation expense will be determined based on the fair value of the stock-based awards and recognized over the vesting period. No stock-based compensation expense related to employee stock options was recognized for the year ended December 31, 2013 or 2012. As of December 31, 2013 there was no unamortized stock-based compensation cost related to non-vested stock awards, as all such instruments were canceled upon emergence from bankruptcy. During the year ended December 31, 2013, no stock options were granted, exercised or forfeited.

Stock option activity for the years ended December 31, 2013 and 2012 is as follows:

Number of

Weighted Average

Aggregate

Exercise Price Per

Intrinsic

Value

Outstanding at January 1, 2012

245,443

3.02

Granted in 2012

—

Exercised

—

Outstanding at December 31, 2012

245,443

3.02

—

Granted in 2013

—

Exercised

—

Canceled

(245,443

)

3.02

Outstanding at December 31, 2013

—

Issuance of Restricted Stock

In April 2013, restricted shares were issued to CBI’s CEO, one CBI board member and one former CBI officer for a portion of their approved claims. The number of shares issued, which totaled 3,328,467, was determined by using a per share price equal to the average of the 30 day closing price of Common Stock and was valued at $152,000.

In September 2012, bonuses, in the form of restricted stock, were issued to a then current CBI employee. Total shares issued were 250,000. The market value of these shares was approximately $5,000.

In December 2010, the Board of Directors approved a resolution allowing former officers of the Company to receive restricted stock in lieu of cash compensation. In August 2012, restricted shares issued to the Company’s CEO under this arrangement were 2,025,000. The market value of these shares was approximately $32,000. In September 2012, restricted shares issued to two independent directors under this arrangement were 625,000. The market value of these shares was approximately $13,000.

Warrants

In connection with a 2007 PIPE financing, CBI issued Class A warrants to purchase 975,000 shares of common stock at an exercise price of $2.85 per share that had an expiration date of May 2013. On March 20, 2013, CBI filed a motion to cancel all outstanding warrants under the terms of the Bankruptcy Code. This motion was approved and entered by the Bankruptcy Court in April 2013. As such, there are no warrants outstanding at December 31, 2013.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	12	Related party transactions:
	On August 1, 2013, the Company formalized amounts due to two former employees and a former director of CBI by issuing three non-interest bearing promissory notes. The two employee notes totaling approximately $62,000 were due on November 1, 2013. Interest will accrue at 18% per annum on any unpaid principal upon default. As of the date of this report, the Company is in default on the aforementioned notes. The Company is now accruing interest in accordance with the specified terms.
	On January 31, 2014, the Company extended the two former employee notes. The amendments include additional principal of approximately $9,000 and are due on March 31, 2014.
	The former director note of approximately $6,000 is due the later of five days following the date on which the Company has raised $1 million, or November 1, 2013. Default interest accrues at a rate of 5% per annum. Both the employee and director note amounts, including accrued interest, are included in notes payable, related party, in the accompanying balance sheet as of December 31, 2013.
	As part of the short-form reincorporation merger with HPPI, certain expenses have been incurred for officer salary, travel, legal and patent expense. These expenses, totaling $366,130, were paid by Hedgepath, LLC on behalf of the newly formed HPPI and are included in due to related party in the accompanying balance sheet as of December 31, 2013. Subsequent to December 31, 3013, working capital advances as of the date of this report from Hedgepath, LLC approximate $100,000, and have been used for officer and employee salaries, legal and professional fees.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2013
Accounting Policies [Abstract]	'
Recent Accounting Pronouncements	'
	Recent accounting pronouncements
	In July 2013, the FASB issued ASU 2013-11– Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). This guidance requires the unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset. When a deferred tax asset is not available, or the asset is not intended to be used for this purpose, an entity should present the unrecognized tax benefit in the financial statements as a liability. The guidance will become effective for us at the beginning of our first quarter of fiscal 2014. The Company does not expect the adoption of this guidance will have a material impact on its financial statements.
	In January 2013, the FASB issued ASU 2013-01 – Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities (“ASU 2013-01”). The amended guidance limits the scope of balance sheet offsetting disclosures to derivatives, repurchase agreements, and securities lending transactions to the extent that they are offset in the financial statements or subject to an enforceable master netting arrangement or similar agreement. The guidance became effective for us at the beginning of our fourth quarter of fiscal 2013. The adoption of this guidance had no impact on the Company’s financial statements.
Estimates	'
	Estimates
	The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
Revenue Recognition	'
	Revenue Recognition
	The Company currently has no ongoing source of revenues. Any miscellaneous income is recognized when earned by the Company.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts.
Research and Development Expenses	'
	Research and Development Expenses
	Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company.
Accounting for Enterprises in Reorganization	'
	Accounting for Enterprises in Reorganization
	Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 852—Reorganizations (“ASC Topic 852”), which is applicable to companies in Chapter 11, generally does not change the manner in which financial statements are prepared. However, it does require that the financial statements for periods subsequent to the filing of the Chapter 11 petition distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of the business. Revenues, expenses, realized gains and losses, and provisions for losses that can be directly associated with the reorganization and restructuring of the business must be reported separately as reorganization items in the statements of operations beginning in the quarter ending March 31, 2011. The balance sheet must distinguish prepetition liabilities subject to compromise from both those prepetition liabilities that are not subject to compromise and from post-petition liabilities. Liabilities that may be affected by a plan of reorganization must be reported at the amounts expected to be allowed by the Bankruptcy Court, even if they may be settled for lesser amounts. In addition, cash flows from reorganization items must be disclosed separately in the statement of cash flows. The Company became subject to ASC Topic 852 effective on January 20, 2011, and has segregated those items as outlined above for all reporting periods after such date. The Company officially emerged from bankruptcy on April 17, 2013, followed by the reincorporation merger, which satisfied the final condition to effectiveness of the Plan as detailed in Note 1.
Income Taxes	'
	Income taxes
	Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the consolidated financial statements for the years ended December 31, 2013 or 2012.

Corporate_overview_Tables

Corporate overview: (Tables)	12 Months Ended
Corporate overview: (Tables)	Dec. 31, 2013
Accounting Policies [Abstract]	'
Computation Basic and Diluted Earnings Per Common Share	'
	The following is a reconciliation of the numerators and denominators of the basic and diluted earnings per common share computations for the years ended December 31, 2013 and 2012.


		2013			2012
	Basic:
	Net (loss) income attributable to common stockholders	$	(1,835,056	)	$	186,366
	Weighted average common shares outstanding		17,940,586			13,646,638

	Basic (loss) earnings per common share	$	(0.10	)	$	0.01


	Diluted:
	Effect of dilutive securities:
	Net (loss) income attributable to common stockholders	$	(1,835,056	)	$	186,366
	Adjustments to income for dilutive options and warrants		—			—

			(1,835,056	)		186,366
	Weighted average common shares outstanding		17,940,586			13,646,638
	Effect of dilutive options and warrants		—			—

	Diluted weighted average common shares outstanding		17,940,586			13,646,638

	Diluted (loss) earnings per common share	$	(0.10	)	$	0.01

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2013
Text Block [Abstract]	'
Property and Equipment relating to CBI	'
	Property and Equipment relating to CBI consisted of the following:


		December 31,
		2013		2012
	Furniture, fixtures, office and computer equipment	$	—	$	53,575
	Other		—		9,077

		$	—	$	62,652

	Less accumulated depreciation		—		(62,652	)

		$	—	$	—

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Difference Between Expected Income Tax Benefits and Income Tax Benefits Recorded in the Financial Statements	'
	The difference between expected income tax benefits and income tax benefits recorded in the financial statements is explained below:


		December 31,
		2013			2012
	Income taxes (benefit) computed at statutory rate	$	(627,319	)	$	—
	State income tax benefit, net		(63,688	)		(347	)
	Change in valuation allowance		691,007			347

		$	—		$	—

Components of Deferred Income Tax Assets and Liabilities	'
	The significant components of deferred income tax assets and liabilities consist of the following:


		December 31,
	Deferred tax assets (liabilities)	2013			2012
	In-process research and development	$	346,801		$	—
	Net operating loss carry forward		407,398			15,994,583
	R&D credit		2,584			52,600

			756,783			16,047,183

	Less: valuation allowance		(756,783	)		(16,047,183	)

		$	—		$	—

Stockholders_Deficit_Tables

Stockholders' Deficit (Tables)	12 Months Ended
Stockholders' Deficit (Tables)	Dec. 31, 2013
Equity [Abstract]	'
Summary of Stock Option Activity	'
	Stock option activity for the years ended December 31, 2013 and 2012 is as follows:


		Number of			Weighted Average		Aggregate
		Shares			Exercise Price Per		Intrinsic
					Share		Value
	Outstanding at January 1, 2012		245,443		$	3.02
	Granted in 2012		—			—
	Exercised		—			—

	Outstanding at December 31, 2012		245,443		$	3.02	$	—


	Granted in 2013		—			—
	Exercised		—			—
	Canceled		(245,443	)		3.02

	Outstanding at December 31, 2013		—		$	—	$	—

Corporate_Overview_Additional_

Corporate Overview - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Mar. 29, 2013

Dec. 31, 2013

Dec. 31, 2012

Jan. 04, 2013

Dec. 31, 2013

Aug. 13, 2013

Mar. 29, 2013

Dec. 31, 2013

Aug. 12, 2013

Dec. 31, 2013

Dec. 31, 2012

Aug. 12, 2013

Aug. 13, 2013

Apr. 07, 2011

Dec. 31, 2013

Hedgepath LLC [Member]

Contribution Agreement [Member]

Commonwealth Biotechnologies, Inc. [Member]

Stock Options And Warrants [Member]

Common Stock [Member]

Preferred Stock [Member]

Series A Preferred Stock [Member]

Mimotopes Pty Limited [Member]

Hedgepath LLC [Member]

Contribution Agreement [Member]

Maximum [Member]

Contribution Agreement [Member]

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Common stock, par value

$0.00

Net selling price of CBI Mimotopes business unit

$850,000

Closing date of sale of business unit

29-Apr-11

Conversion ratio

Issuance of HPPI's shares to CBI's shareholders, stock

340,000,000

10,000,000

Par value assigned stock after merger

$0.00

Auction fees paid by Hedgepath, LLC to CBI

30,000

Percentage of voting rights retained by the prior stockholders of CBI in HPPI

10.00%

Total percentage of issued and outstanding shares of HPPI common stock

100.00%

Ownership interest exchanged for the assets contributed

90.00%

Percentage of convertible preferred stock representing diluted voting securities

90.00%

Number of shares in exchange for right to receive

170,001

Shares of common stock under contribution agreement after conversion of preferred stock

18,888,971

15,560,504

170,000,739

Expenses incurred for acquiring assets and developing ITRA business opportunity

100,000

Expenses incurred on technical and medical consulting

82,500

Expenses incurred on option fees

15,000

Hedgepath, LLC's claim against CBI

52,500

Value of securities planned to offer as a part of contribution agreement

5,000,000

Maximum number of days after determination of valuation within which the securities should be offered

'5 days

Research and development cost to be expensed for the execution of contribution agreement

$1,000,000

Percentage of market capitalization considered for calculating the Research and development cost

90.00%

Antidilutive securities excluded from computation of earnings per common share

1,220,443

Corporate_Overview_Computation

Corporate Overview - Computation Basic and Diluted Earnings Per Common Share (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Basic:	'	'
Net (loss) income attributable to common stockholders	($1,835,056)	$186,366
Weighted average common shares outstanding	17,940,586	13,646,638
Basic (loss) earnings per common share	($0.10)	$0.01
Effect of dilutive securities:	'	'
Net (loss) income attributable to common stockholders	-1,835,056	186,366
Adjustments to income for dilutive options and warrants	'	'
Diluted Securities	($1,835,056)	$186,366
Weighted average common shares outstanding	17,940,586	13,646,638
Effect of dilutive options and warrants	'	'
Diluted weighted average common shares outstanding	17,940,586	13,646,638
Diluted (loss) earnings per common share	($0.10)	$0.01

Recovered_Sheet1

Liquidity and Management's Plans - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reorganizations [Abstract]	'	'	'
Cash and cash equivalents	$217	$857,702	$1,321,968
Working capital advances from Hedgepath, LLC	$100,000	'	'

Supply_and_License_Agreement_A

Supply and License Agreement - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Supply And License Agreement Commitment [Line Items]	'
Amount raised from equity financing	$5,000,000
Supply and License Agreement from the date of the first commercial sale of the product	'10 years
Maximum reimbursement expenses allowed	$100,000
Percentage of Issued and outstanding shares of capital stock	30.00%
Minimum [Member]	'
Supply And License Agreement Commitment [Line Items]	'
Supply and License Agreement amendment effective date	28-Feb-14
Maximum [Member]	'
Supply And License Agreement Commitment [Line Items]	'
Supply and License Agreement amendment effective date	25-Apr-14
Series A Preferred Stock [Member]	'
Supply And License Agreement Commitment [Line Items]	'
Company's Series A Preferred Stock issued under Supply and License Agreement	170,001
Company's Series A Preferred Stock, par value under Supply and License Agreement	$0.00
Percentage of Series A Preferred Stock representing on an as fully converted, fully diluted basis	45.00%

Gain_on_Reorganization_Additio

Gain on Reorganization - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Reorganizations [Abstract]	'	'
Recognized gains	$166,676	$747,036

Debt_Additional_Information_De

Debt- Additional Information (Detail) (USD $)	0 Months Ended
Debt- Additional Information (Detail) (USD $)	Sep. 30, 2012	Sep. 04, 2008
Equity Method Investments And Cost Method Investments [Abstract]	'	'
Issuance of convertible promissory note	'	$500,000
Written off principal and accrued interest amount	$666,667	'

Property_and_Equipment_Propert

Property and Equipment - Property and Equipment relating to CBI (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Furniture, fixtures, office and computer equipment	'	$62,652
Less accumulated depreciation	'	-62,652
Property and equipment,Net	'	'
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Furniture, fixtures, office and computer equipment	'	53,575
Other Capitalized Property Plant and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Furniture, fixtures, office and computer equipment	'	$9,077

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property Plant And Equipment Useful Life And Values [Abstract]	'	'
Depreciation expense	$0	$0

Other_Assets_Additional_Inform

Other Assets - Additional Information (Detail) (USD $)	Dec. 31, 2012
Cash And Cash Equivalents [Abstract]	'
Other current assets relating to cash held in escrow	$75,000

Income_Taxes_Difference_betwee

Income Taxes - Difference between expected income tax benefits and income tax benefits recorded in the financial statements (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Income taxes (benefit) computed at statutory rate	($627,319)	'
State income tax benefit, net	-63,688	-347
Change in valuation allowance	691,007	347
Expected income tax benefits and income tax benefits recorded	'	'

Income_Taxes_Components_of_def

Income Taxes - Components of deferred income tax assets and liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
In-process research and development	$346,801	'
Net operating loss carry forward	407,398	15,994,583
R&D credit	2,584	52,600
Deferred tax assets gross	756,783	16,047,183
Less: valuation allowance	-756,783	-16,047,183
Deferred tax assets, net	'	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2013
Income Taxes [Line Items]	'
NOLs used to offset taxable income	$35,000
Domestic Tax Authority [Member]	'
Income Taxes [Line Items]	'
Net operating loss carryforward	1,100,000
State and Local Jurisdiction [Member]	'
Income Taxes [Line Items]	'
Net operating loss carryforward	$1,100,000

Chapter_11_Information_Additio

Chapter 11 Information - Additional Information (Detail) (USD $)	1 Months Ended		12 Months Ended
	Apr. 30, 2013	Sep. 30, 2012	Dec. 31, 2013	Dec. 31, 2012
Emergence From Chapter Eleven [Line Items]	'	'	'	'
Pre-petition claims associated with the bankruptcy in cash	'	'	$357,265	'
Pre-petition claims associated with the bankruptcy in common Stock	'	'	152,000	'
Common stock value in average of the company's stock price	'30 days	'	'30 days	'
Gain on reorganization	'	'	166,676	'
Gain on extinguishment	'	666,667	'	666,667
Realized gains	'	'	'	80,369
Convertible Promissory Notes [Member]	'	'	'	'
Emergence From Chapter Eleven [Line Items]	'	'	'	'
Principal amount	'	500,000	'	'
Interest	'	$166,667	'	'

Stockholders_Deficit_Additiona

Stockholders' Deficit - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

Apr. 30, 2013

Sep. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Apr. 30, 2013

Aug. 31, 2012

Sep. 30, 2012

Jul. 16, 2013

Dec. 31, 2013

Commonwealth Biotechnologies, Inc. [Member]

CEO [Member]

Employees [Member]

2002 Stock Incentive Plan [Member]

2007 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

Executives

Directors

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Period of cancellation of options

'90 days

Options cancellation date

16-Jul-13

Option outstanding under 2009 stock incentive plan

245,443

Minimum exercise price of the fair market value of shares

100.00%

Minimum exercise price for incentive stock options granted to persons who own more than 10% of the company's voting stock

110.00%

Minimum percentage of the company's voting stock for grant of incentive stock options

10.00%

Options granted vesting period

'3 years

Options exercisable period

'10 years

Maximum period for grant of incentive stock options

'5 years

Stock-based compensation expense related to employee stock options

Unamortized stock-based compensation cost related to non-vested stock awards

Stock options were granted

Stock options were exercised or forfeited

Period of average closing price of common stock

'30 days

Number of board member to whom restricted shares were issued

Number of former officer to whom restricted shares were issued

Restricted stock share issued

625,000

3,328,467

2,025,000

250,000

Market value of restricted stock

$13,000

$152,000

$32,000

$5,000

Number of security called by warrant

975,000

Class of warrant exercise price

2.85

Warrants outstanding

Stockholders_Deficit_Summary_o

Stockholders' Deficit - Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Equity [Abstract]	'	'
Outstanding Shares, Beginning Balance	245,443	245,443
Outstanding Shares, Granted	0	'
Outstanding Shares, Exercised	'	'
Outstanding Shares, Canceled	-245,443	'
Outstanding Shares, Ending Balance	'	245,443
Weighted Average Exercise Price, Beginning balance	$3.02	$3.02
Weighted Average Exercise Price, Granted	'	'
Weighted Average Exercise Price, Exercisable	'	'
Weighted Average Exercise Price, Cancelled	$3.02	'
Weighted Average Exercise Price, Ending balance	'	$3.02
Aggregate Intrinsic Value, Ending balance	'	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Aug. 01, 2013	Aug. 01, 2013	Jan. 31, 2014	Dec. 31, 2013	Aug. 01, 2013
			Promissory Notes [Member]	Employees [Member]	Employees [Member]	Hedgepath LLC [Member]	Board Member [Member]
			Employees	Promissory Notes [Member]	Promissory Notes [Member]		Promissory Notes [Member]
			Promissory_Notes		Subsequent Event [Member]
Related Party Transaction [Line Items]	'	'	'	'	'	'	'
Number of non-interest promissory notes	'	'	3	'	'	'	'
Number of employees for notes	'	'	2	'	'	'	'
Notes due	'	'	'	$62,000	$9,000	'	$6,000
Interest to be paid on default of promissory note	'	'	'	18.00%	'	'	5.00%
Promissory note due period	'	'	'5 days	'	'	'	'
Fund amount to be raise under condition one	'	'	1,000,000	'	'	'	'
Expected maturity date under condition two	'	'	1-Nov-13	'	'	'	'
Due to Hedgepath LLC	366,130	'	'	'	'	366,130	'
Working capital advances	$100,000	'	'	'	'	$100,000	'